The global peptide therapeutics market was valued at USD 28.83 billion in 2020 and is projected to grow at a CAGR of 9.8% during the forecast period. Factors driving the growth of the peptide therapeutics market include increasing popularity of malignancy and metabolic ailments, implementation of innovative platforms that improve next-generation protein and growing research and development spending by government and key companies.
The global peptide therapeutics market is segmented based on type, application and route of administration. On the basis of route of administration, the market is segmented into parenteral, oral and other routes of administration. The biopharmaceuticals corporations are unceasingly discovering new procedures of drug delivery applicable to peptides. Innovative drug delivery technologies are nowadays being evaluated for effectiveness with engineered molecules taking radical PEGylation, in an endeavor to develop drug delivery performance and patient compliance through superior methods of drug delivery.
Regionally, North America accounted for the largest market share of the global peptide therapeutics market attributable to engrained biopharmaceutical & pharmaceutical business in this region. Leading players of the global peptide therapeutics market include Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Lonza Inc., Bristol-Myers Squibb, Sanofi, AstraZeneca PLC, among others.
Peptide Therapeutics Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 60.62 billion|
|Growth Rate||CAGR of 9.8% during 2021-2028|
|Segment Covered||Type, Application, Route of Administration, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, Middle East & Africa|
|Key Players Profiled||Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., Lonza Inc., Bristol-Myers Squibb, Sanofi, AstraZeneca PLC, among others.|
Key segments of the global peptide therapeutics market
Type Overview, 2018-2028 (USD Billion)
Application Overview, 2018-2028 (USD Billion)
- Gastrointestinal Disorders
- Neurological Disorders
- Metabolic Disorders
- Other Applications
Route of Administration Overview, 2018-2028 (USD Billion)
- Other Routes of Administration
Regional Overview, 2018-2028 (USD Billion)
- North America
- United Kingdom
- Asia Pacific
- Latin America
- Middle East & Africa
- South Africa
Reasons for the study
- Increasing prevalence of cancer and metabolic disorders
- Rising investments in research and development of novel drugs
- High cost of developing drugs and stringent regulatory requirements for drug approval?
What does the report include?
- The study on the global peptide therapeutics market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of type, application and route of administration. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global peptide therapeutics market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global peptide therapeutics market
Consultants, analysts, researchers, and academicians looking for insights shaping the global peptide therapeutics market
Protein–protein interactions (PPIs) are the underpinning of fundamentally all cellular process. These biochemical procedures time and again comprise of stimulated receptors that indirectly or directly control a chain of enzymatic events from transcription of nucleic acids, ion carriage, and numerous post-translational alterations of translated proteins. Drugs that bind specially to such receptors can act as agonists or antagonists, with downstream penalties on cellular conduct. Peptides and small molecules that hinder with PPIs are therefore in high demand as therapeutic agents in pharmaceutical businesses owing to their prospective to moderate disease-associated protein interfaces. Furthermore to the usage of peptides as medicines or in diagnostics, these molecules are playing a progressively vital role as drug delivery systems and as the base for innovative biomaterials using broad probable applications in medicine. Accumulating evidence has recommended that improved identification of targetable disease-associated PPIs and optimization of peptide drug binding features will be important aspects for their clinical triumph.
On the basis of application, the market is segmented into gastrointestinal disorders, neurological disorders, metabolic disorders, cancer and other applications. Oncology, with five drugs (two radio peptides and two ADCs), metabolism (three), and endocrinology (two) are the most frequent medical indications for peptides. However, cardiovascular conditions, gastroenterology, bone diseases, dermatology, and sexual dysfunction are also targeted by peptides. Of note, between 2015 and 2019, several of the new peptide-based drugs accepted by the FDA came about from the efforts of academic groups. This highlights the importance of fostering solid and efficient cooperation channels between academia and industry with the aim to maintain and improve the well-being of society. In addition to the use of peptides as drugs or in diagnostics, these molecules are playing an increasingly important role as drug delivery systems and as the base for new biomaterials with broad potential applications in medicine.
North America accounted for the largest share of the global peptide therapeutics market in 2020. Moreover, Asia is likely to show lucrative growth during the forecast period.
Cancer is a major public health problem and is the second leading cause of death in the United States and worldwide. Cancer is responsible for over 8.8 and 1.6 million deaths globally and domestically and nearly one in six deaths are attributable to cancer. In the United States, prostate, lung, and colorectal cancers account for 44% of all cases in men, with prostate cancer accounting for one in five new diagnoses. Breast, lung, and colorectal cancers account for one-half of all cases in women, with breast cancer accounting for 29% of new diagnoses. Peptide therapeutics are being widely explored to develop novel therapeutics for cancer.